Breaking News, Collaborations & Alliances

Porton Advanced, Yinjia Biosciences Partner to Enhance CDMO Technology Platform

Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.

Porton Advanced Solutions and Yinjia Biosciences Co., Ltd. entered into a strategic partnership to develop core protein raw materials for cell and gene therapy (CGT) and test reagent products for quality control and evaluation systems to accelerate the development and commercialization of CGT. Porton Advanced CDMO offers end-to-end gene and cell therapy services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy. Yinjia Biosciences focuses on h...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters